Abstract | Keywords | Export | Availability | Bookmark

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic strategies.

apolipoprotein --- lipids --- risk stratification --- proprotein convertase subtilisin-kexin type 9 (PCSK9) --- vaspin --- sphingolipids --- PCSK9 --- ceramides --- atrial fibrillation --- circular RNA --- STEMI --- cholesterol --- lipoproteins --- cardiovascular disease (CVD) --- coronary artery bypass grafting --- atherosclerosis --- statin --- LDL subfractions --- acute kidney injury --- dyslipidemia --- gene expression --- NSTEMI --- NAFLD --- hyperlipidemia --- nonstatin --- cholesteryl ester transfer protein --- low-density lipoprotein cholesterol --- anacetrapib --- HDL --- acute coronary syndrome --- miRNA --- cardiovascular risk --- pleiotropic actions --- genetic --- ABCA1 --- sdLDL --- cardiovascular disease --- proprotein convertase subtilisin/kexin type 9 --- inclisiran --- reverse cholesterol transport --- sterol --- small interfering RNA (siRNA) --- RNA-binding proteins --- cardiovascular diseases --- NASH --- low-density lipoprotein-cholesterol (LDL-C) --- stroke --- nutrigenetics --- type 2 diabetes --- statins --- sphingomyelin --- hepatic fibrosis --- diabetes